WHY WE WILL SEE $3 BY THE END OF THIS WEEK

HODL - CU6 to $3 by end of this week — bull case

Current setup: CU6 is already basically sitting on the doorstep. Last quoted around $2.90, so $3 is only about 3.4% upside from here, not some insane multi-bagger target. It also traded as high as $3.00 on 15 May, meaning the level has already been tested very recently.

1. $3 is a near-term technical magnet, not a fantasy target
This is the cleanest part of the bull case. The market has already shown it is willing to trade CU6 at $3. If buyers step back in and volume holds, $3 becomes a very realistic retest zone. The stock does not need a huge re-rate; it only needs a modest push through a recent intraday high.

2. Balance sheet is strong — no obvious CR overhang right now
CU6 is not one of those busted biotechs running on fumes. Clarity reported $197.8m cash at 31 March 2026, with March-quarter net operating cash outflows of $25.5m. That is still a heavy burn, but the cash runway is meaningful. It also received a $9.8m R&D tax incentive refund on 14 May 2026, which is non-dilutive cash.

3. Last major raise was not a desperate discount raise
This matters. In July 2025, Clarity completed a $203m institutional placement at $4.20 per share, which was at a 2.2% premium to the last close and an 18% premium to the 15-day VWAP. That is very different from a typical ASX biotech “please save us” capital raise. It showed institutional support at a price materially above today’s ~$2.90 level.

4. Institutional register support is real
Market Index shows major names on the register including JP Morgan Chase & Co., Citigroup Global Markets Australia, State Street, and Vanguard across substantial holder notices in 2025. That does not guarantee the price goes up, but it supports the idea that CU6 is not purely a retail pump stock.

5. Commercial manufacturing agreement adds “real company” credibility
In April 2026, Clarity announced a commercial manufacturing agreement for 64Cu-SAR-bisPSMA, with stated capacity of up to 650,000 doses per year across facilities. The market initially sold the announcement, but fundamentally it supports the bigger story: Clarity is preparing infrastructure for potential large-scale commercial rollout, assuming trial and regulatory success.

6. The radiopharma theme remains hot
CU6 is in oncology radiopharmaceuticals, not some dead sector. The bull angle is that investors may continue rotating into names with strong cash, late-stage clinical assets, and potential US commercial pathways. In a risk-on biotech tape, a move from $2.90 to $3.00 is not demanding.

Postable version

CU6 at $3 by the end of this week is not a wild call. It is sitting around $2.60, and $3 was already touched recently. That means we are not talking about a massive re-rate — we are talking about a small push back into a level the market has already accepted.

The key difference with CU6 is that it is not a typical cash-starved ASX biotech. The company had $197.8m cash at 31 March 2026, received another $9.8m R&D tax incentive refund, and its last major institutional placement was done at $4.20 — at a premium, not a discount. That is a huge signal compared with the usual biotech raise-and-dump rubbish.

On top of that, CU6 has serious institutional names on the register and is building out manufacturing capacity for its key radiopharmaceutical programs. The April manufacturing agreement was initially sold down, but strategically it points to preparation for commercial scale, not science-project mode.

So the bull case is simple: strong balance sheet, institutional support, no obvious near-term CR fear, major clinical/commercial pipeline, and a $3 level that has already been tested. If volume comes in, $3 this week is absolutely within reach.

$3 this week is GUARANTEED BY FRIDAY. The clean bull case is that it only needs a small move.

If you sell here, your weak hands are selling at the BOTTOM.